6 June 2024 Tender Notification
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2023/24 Invitation to Tender dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of June 2024 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
- 2024 06 06 June Part I Notification v2 [PDF 196 KB]
2023/24 Tender – Principal Supply Status applies until 30 June 2027
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to currently listed pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Hydroxychloroquine sulphate |
Tab 200 mg; 100 tablet bottle pack |
$8.78 |
$7.80 |
Ipca-Hydroxychloroquine (Miro) |
1 December 2024 |
1 May 2025 |
Plaquenil (Sanofi) |
|
Pazopanib1 |
Tab 200 mg; 28 tablet blister pack |
$1,334.70 |
$172.88 |
Pazopanib Teva (Teva) |
1 December 2024 |
1 May 2025 |
Votrient (Novartis) |
|
Pazopanib1 |
Tab 400 mg; 28 tablet blister pack |
$2,669.40 |
$464.00 |
Pazopanib Teva (Teva) |
1 December 2024 |
1 May 2025 |
Votrient (Novartis) |
|
1Brand Switch Fee of $4.50 is payable for this product from 1 May 2025 until 1 August 2025. |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
2. Tenders awarded pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Bendamustine2 |
Inj 25 mg vial; 1 vial pack |
$77.00 |
$50.50 |
Bendamustine Sandoz (Sandoz) |
5% |
1 November 2024 |
1 April 2025 |
Ribomustin (Janssen-Cilag) |
|
Bendamustine2 |
Inj 100 mg vial; 1 vial pack |
$308.00 |
$200.20 |
Bendamustine Sandoz (Sandoz) |
5% |
1 November 2024 |
1 April 2025 |
Ribomustin (Janssen-Cilag) |
|
Hydroxychloroquine sulphate |
Tab 200 mg; 100 tablet bottle pack |
$8.78 |
$7.80 |
Ipca-Hydroxychloroquine (Miro) |
5% |
1 December 2024 |
1 May 2025 |
Plaquenil (Sanofi) |
|
Pazopanib |
Tab 200 mg; 28 tablet blister pack |
$1,334.70 |
$172.88 |
Pazopanib Teva (Teva) |
5% |
1 December 2024 |
1 May 2025 |
Votrient (Novartis) |
|
Pazopanib |
Tab 400 mg; 28 tablet blister pack |
$2,669.40 |
$464.00 |
Pazopanib Teva (Teva) |
5% |
1 December 2024 |
1 May 2025 |
Votrient (Novartis) |
|
Pemetrexed3 |
Inj 100 mg vial; 1 vial pack |
$60.89 |
$8.99 |
Pemetrexed-AFT (AFT) |
5% |
1 November 2024 |
1 April 2025 |
Juno Pemetrexed (Juno) |
|
Pemetrexed3 |
Inj 500 mg vial; 1 vial pack |
$217.77 |
$29.99 |
Pemetrexed-AFT (AFT) |
5% |
1 November 2024 |
1 April 2025 |
Juno Pemetrexed (Juno) |
|
2The price and subsidy of bendamustine (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 November 2024. The subsidy of bendamustine inj 1 mg for ECP (Baxter) will be reduced from $3.23 per 1 mg to $2.11 per 1 mg from 1 April 2025 in Section B of the Pharmaceutical Scheule. 3The price and subsidy of pemetrexed (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 November 2024. The subsidy of pemetrexed inj 1 mg for ECP (Baxter) will be reduced from $0.55 per 1 mg to $0.11 per 1 mg from 1 April 2025 in Section B of the Pharmaceutical Scheule. |
||||||||
For products included in the 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.